Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.

White JB, Fleming R, Masterson L, Ruddle BT, Zhong H, Fazenbaker C, Strout P, Rosenthal K, Reed M, Muniz-Medina V, Howard P, Dixit R, Wu H, Hinrichs MJ, Gao C, Dimasi N.

MAbs. 2019 Apr;11(3):500-515. doi: 10.1080/19420862.2019.1578611. Epub 2019 Mar 5.

PMID:
30835621
2.

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.

Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.

Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.

PMID:
30352801
3.

Tuning the Diels-Alder Reaction for Bioconjugation to Maleimide Drug-Linkers.

St Amant AH, Lemen D, Florinas S, Mao S, Fazenbaker C, Zhong H, Wu H, Gao C, Christie RJ, Read de Alaniz J.

Bioconjug Chem. 2018 Jul 18;29(7):2406-2414. doi: 10.1021/acs.bioconjchem.8b00320. Epub 2018 Jun 22.

4.

Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.

Dimasi N, Fleming R, Zhong H, Bezabeh B, Kinneer K, Christie RJ, Fazenbaker C, Wu H, Gao C.

Mol Pharm. 2017 May 1;14(5):1501-1516. doi: 10.1021/acs.molpharmaceut.6b00995. Epub 2017 Mar 16.

PMID:
28245132
5.

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody.

Kasturirangan S, Rainey GJ, Xu L, Wang X, Portnoff A, Chen T, Fazenbaker C, Zhong H, Bee J, Zeng Z, Jenne C, Wu H, Gao C.

J Biol Chem. 2017 Mar 10;292(10):4361-4370. doi: 10.1074/jbc.M116.770628. Epub 2017 Jan 18.

6.

Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.

Bezabeh B, Fleming R, Fazenbaker C, Zhong H, Coffman K, Yu XQ, Leow CC, Gibson N, Wilson S, Stover CK, Wu H, Gao C, Dimasi N.

MAbs. 2017 Feb/Mar;9(2):240-256. doi: 10.1080/19420862.2016.1270492.

7.

Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies.

Zhong H, Fazenbaker C, Chen C, Breen S, Huang J, Yao X, Ren P, Yao Y, Herbst R, Hollingsworth RE.

Oncogene. 2017 Feb 9;36(6):797-806. doi: 10.1038/onc.2016.248. Epub 2016 Jul 11.

PMID:
27399333
8.

MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas.

Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, Yao Y, Hollingsworth RE.

Mol Cancer Ther. 2014 Nov;13(11):2662-73. doi: 10.1158/1535-7163.MCT-14-0144. Epub 2014 Sep 5. Erratum in: Mol Cancer Ther. 2015 Mar;14(3):844.

9.

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y.

Int J Oncol. 2012 May;40(5):1321-30. doi: 10.3892/ijo.2012.1366. Epub 2012 Feb 10.

PMID:
22327175
10.

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y.

Mol Cancer Ther. 2009 Aug;8(8):2131-41. doi: 10.1158/1535-7163.MCT-08-1038. Epub 2009 Aug 11.

11.

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK.

J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29.

12.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

13.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA.

Cancer Res. 2008 Nov 15;68(22):9367-74. doi: 10.1158/0008-5472.CAN-08-1933.

14.

Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.

Cassatt DR, Fazenbaker CA, Bachy CM, Kifle G, McCarthy MP.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):901-7.

PMID:
15708273
15.
16.

Effects of dose and schedule on the efficacy of ethyol: preclinical studies.

Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM.

Semin Oncol. 2003 Dec;30(6 Suppl 18):31-9. Review.

PMID:
14727238
17.

Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.

Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):794-802.

PMID:
14529786
18.

Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.

Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM.

Semin Oncol. 2002 Dec;29(6 Suppl 19):2-8. Review.

PMID:
12577236
19.

Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.

Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS.

Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):97-102.

PMID:
11917293
20.

Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies.

Ulbrandt ND, Cassatt DR, Patel NK, Roberts WC, Bachy CM, Fazenbaker CA, Hanson MS.

Infect Immun. 2001 Aug;69(8):4799-807.

Supplemental Content

Loading ...
Support Center